Effect of 3 Single‐Dose Regimens of Opicapone on Levodopa Pharmacokinetics, Catechol‐O‐Methyltransferase Activity and Motor Response in Patients With Parkinson Disease

Publisher： John Wiley & Sons Inc

E-ISSN： 2160-7648|5|3|232-240

ISSN： 2160-763X

Source： Clinical Pharmacology In Drug Development, Vol.5, Iss.3, 2016-05, pp. : 232-240

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Entacapone, a novel catechol-O-methyltransferase inhibitor for Parkinson's disease, does not impair mitochondrial energy production

By Nissinen E.   Kaheinen P.   Penttila K.E.   Kaivola J.   Linden I.-B.  

European Journal of Pharmacology, Vol. 340, Iss. 2, 1997-12 ,pp. : 287-294

Elsevier

Access to resources Recommend Favorite

Entacapone, a catechol-O-methyltransferase inhibitor for treating Parkinson’s disease: review and current status

By Gottwald M.D.  

Expert Opinion on Investigational Drugs, Vol. 8, Iss. 4, 1999-04 ,pp. : 453-462

Informa Healthcare

Access to resources Recommend Favorite

Role of Catechol-O-Methyltransferase (COMT)-Dependent Processes in Parkinson’s Disease and L-DOPA Treatment

By  

CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol. 11, Iss. 3, 2012-05 ,pp. : 251-263

Bentham Science Publishers

Access to resources Recommend Favorite

Inhibitors of Catechol-O-Methyltransferase

By  

CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol. 11, Iss. 3, 2012-05 ,pp. : 324-332

Bentham Science Publishers

Access to resources Recommend Favorite

Catechol- O -Methyltransferase Inhibitors in Parkinson's Disease: Guidelines for Effective Use

By Davis T.L.  

CNS Drugs, Vol. 10, Iss. 4, 1998-10 ,pp. : 239-246

Adis International

Access to resources Recommend Favorite